NSCLC. Adjuvant/Locally Advanced

Rafael Santana-Davila.
Associate Professor Of Medicine.
University of Washington/Fred Hutchinson Cancer Center.
SCCA
rafaelsd@uw.edu
Stage I to stage IIIA

• Treatment goal for patients with stage I to III is curative. Although prognosis is still dismal.

• Between 40-50% of patients with stage IB, 55-70% of patients with stage II and and the great majority of patients with stage IIIA will have recurrent disease if surgery is the only modality of treatment.

• Important to remember that this is a very heterogenous group with likely different prognosis.

• The role of adjuvant chemotherapy was been widely studied and although the benefits are small they have been been consistent.
Heterogenous group

T4, NO, MO Stage IIIA

T2, N2, MO Stage IIIA
Staging of the mediastinum.

- Essential to stage via endoscopic bronchial ultrasound or mediastinoscopy prior to a resection.
- Invasive mediastinal staging is indicated for all patients with central tumors; those with potentially resectable T2, T3, and T4 tumors; and those with tumors with enlarged hilar lymph nodes by CT and/or clinical N1 involvement by PET, even if the mediastinum appears clean by both CT and PET criteria.
Clinical evidence for adjuvant treatment.

• Lung Adjuvant Cisplatin Evaluation (LACE) group performed a pooled analysis of individual patient data from the largest cisplatin-based adjuvant trials performed since 1995, including 5 trials, with a total of 4584 patients.

• Established a reduction in mortality of 5.4% at 5 years in patients who received chemotherapy compared with those who did not (hazard ratio [HR] = 0.89; 95% CI, 0.82–0.96; \( P = .005 \)).

• No benefit in stage IA. But present in stage IB (0.93; 95% CI, 0.78 to 1.10) stage II (HR= 0.83; 95% CI, 0.73 to 0.95) and stage III (HR= 0.83; 95% CI, 0.72 to 0.94)

Pignon, JCO, 2008
Clinical evidence

• A follow-up meta-analysis in 2010 confirmed the benefits of adjuvant chemotherapy after evaluating 34 trials and 8447 patients and showing an increase in overall survival by 4% at 5 years with the addition of adjuvant chemotherapy.

• Currently the recommendation is for a platinum doublet.

• Vinorelbine is the most widely studied partner but pemetrexed is preferred for non-squamous and gemcitabine or docetaxel for squamous.

• Cisplatin is preferred. Concern for less activity for carbo. Use of carboplatin is controversial and should only be reserved for patients in special circumstances.
Stage IB

• Controversial.

• Only study using carboplatin and paclitaxel was negative. Subgroup analysis showed only benefit in patients with large tumors (>more then 4 cm).

Stage II and III with N0 disease

• Another area of controversy.
• If there is no lymph node metastasis likely lower risk of distal metastasis.
• Most analysis come from restrospective studies with mixed results.
• However bias plays an important roles in this setting
• Important to know how much lymph nodes were actually resected.
PORT

• If margins are negative there is no role for patients with stage II disease.

• In patients with stage IIIA/IIIB disease, there is a benefit for mediastinal radiation. Most is done sequentially to diminish toxicity after surgery.
Neoadjuvant treatment

• Benefits include prognostication, potential for downstaging.
• However is difficult to establish in which patients this should be the standard.
• Best subset of patients such as those with single station stage IIIA disease, superior sulcus tumors or those with chest wall invasion in the setting of N1 nodal involvement.
• Key, as in the management of all patients with early stage disease, is the use of a multidisciplinary team.
Immunotherapy

• Several clinical trials are establishing the role of immunotherapy both in the neoadjuvant and adjuvant studies.
• Several early phase studies have shown an increase in the rate of complete responses when neoadjuvant immunotherapy is used.
  • Nivo or Nivo/Ipi. NCT01822496
  • Pembrolizumab. NCT03425643
  • Durvalumab. NCT03800134.
  • Atezolizumab. NCT03456063
Special populations

- EGFR

ADAURA Phase III double-blind study design

**Patients with completely resected stage IIIA, II, I NSCLC, with or without adjuvant chemotherapy**

- Key inclusion criteria:
  - ≥19 years (Japan / Tazien: ≥20)
  - WHO performance status 0/1
  - Confirmed primary non-squamous NSCLC (Excluded LUSQR)
  - Brain imaging, if not completed pre-operatively
  - Complete resection with negative margins
  - Max. interval between surgery and randomization
  - 10 weeks without adjuvant chemotherapy
  - ≥20 weeks with adjuvant chemotherapy

**Randomization**

- 1:1 (N=682)
- Osimertinib: 80 mg. once daily
- Placebo: once daily

**Planned treatment duration:** 3 years

**Treatment continues until:**
- Disease recurrence
- Treatment completed
- Discontinuation criteria met

**Follow up:**
- Until recurrence: Week 12 and 24, then every 24 weeks to 5 years, then yearly
- After recurrence: every 24 weeks for 5 years, then yearly

Endpoints

- **Primary:** DFS, by investigator assessment, in stage IIA patients; designed for superiority under the assumed DFS HR of 0.70
- **Secondary:** DFS in the overall population, DFS at 2, 3, 4, and 5 years, OS, safety, health-related quality of life

- Following IDMC recommendation, the study was unblinded early due to efficacy; here we report an unplanned interim analysis
- At the time of unblinding the study had completed enrollment and all patients were followed up for at least 1 year
So, now what?

• How will OS be affected, how many patients will cross-over?
• Currently designated as a breakthrough therapy by the FDA.
• Osimertinib is well tolerated and has an impressive DFS advantage.
• What is the role of chemotherapy? 😜
• In an ideal world (where consideration for costs doesn’t exist) it would be a clear standard.
• Cost is $1,200,000 for 3 years of therapy.
• Gulp. 😢
• This evidence should not be extrapolated to other cancers that have mutations drivers.
Conclusion regarding adjuvant therapy.

• Benefit is small but exists.
• Proper staging is essential.
• Patients should be managed by a multidisciplinary team.
• Cisplatin doublet is the preferred regimen for patients that are candidates.
• Immunotherapy and targeted therapy are likely to play a role in the near future.
Locally advanced disease

- For patients with inoperable stage II disease, multistation stage IIIA or stage IIIB disease the standard of care is chemotherapy and radiation.
- Several clinical trials have established that concurrent therapy offers a survival advantage over sequential treatment. At the price of increase adverse events.
- Important for patients who have poor PS.
Role of higher dose of radiation

• Increased dose of radiation is not beneficial. RTOG 0617 randomized patients to either standard-dose (60 Gy/30 daily fractions) or high-dose RT (74 Gy/37 daily fractions).

• High-dose (74 Gy) RT was associated with a shorter survival and an increased risk of death compared with conventional-dose (60 Gy) RT (median, 20 versus 29 months; HR 1.38, 95% CI 1.09-1.76).
Chemotherapy

• Platinum-doublet is the standard.
• Long debate as to what chemotherapy is the best partner along side with radiation.
• Before the era of immunotherapy:
  • Cisplatin-etoposide likely equal to carboplatin and paclitaxel.
  • More adverse events in the former and need for additional consolidation in the latter.
• Few randomized studies have actually been conducted.
• PROCLAIM. Compared EP vs cisplatin-pemetrexed in 598 patients
PROCLAIM

Senana, JCO, 2016
Patients in the pemetrexed arm received consolidation pemetrexed alone.
Role of immunotherapy

• PACIFIC study was the most important game changer.
• 713 patients were randomized 2:1 to receive durvalumab after the concurrent phase of radiation.
• Chemotherapy partners was dealer’s choice but no consolidation treatment was allowed.
Updated Analysis of Time to Death or Distant Metastasis in the Intention-to-Treat Population.

<table>
<thead>
<tr>
<th>Duration</th>
<th>Durvalumab</th>
<th>Placebo</th>
<th>Stratified hazard ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>mo</td>
<td>28.3 (24.0–34.9)</td>
<td>16.2 (12.5–21.1)</td>
<td>0.53 (95% CI, 0.41–0.68)</td>
</tr>
</tbody>
</table>

No. of Events/Total No. of Patients

- Durvalumab: 182/476
- Placebo: 126/237

No. at Risk

- Durvalumab: 476, 419, 357, 316, 259, 223, 194, 163, 129, 92, 46, 25, 1, 0
- Placebo: 237, 189, 139, 118, 95, 77, 64, 54, 39, 27, 12, 5, 0
# Table 3. Adverse Events of Any Cause.

<table>
<thead>
<tr>
<th>Event</th>
<th>Durvalumab (N = 475)</th>
<th>Placebo (N = 234)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Grade 3 or 4</td>
</tr>
<tr>
<td></td>
<td>number of patients with event (percent)</td>
<td></td>
</tr>
<tr>
<td>Any event</td>
<td>460 (96.8)</td>
<td>142 (29.9)</td>
</tr>
<tr>
<td>Cough</td>
<td>168 (35.4)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>Pneumonitis or radiation pneumonitis†</td>
<td>161 (33.9)</td>
<td>16 (3.4)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>113 (23.8)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>106 (22.3)</td>
<td>7 (1.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>87 (18.3)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>70 (14.7)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>68 (14.3)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Nausea</td>
<td>66 (13.9)</td>
<td>0</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>62 (13.1)</td>
<td>21 (4.4)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>59 (12.4)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>58 (12.2)</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>58 (12.2)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>58 (12.2)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Constipation</td>
<td>56 (11.8)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>55 (11.6)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Headache</td>
<td>52 (10.9)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>51 (10.7)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Back pain</td>
<td>50 (10.5)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>39 (8.2)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Anemia</td>
<td>36 (7.6)</td>
<td>14 (2.9)</td>
</tr>
</tbody>
</table>
PDL1 status.

- OS favored durvalumab, versus placebo, across all PD-L1 subgroups but one, patients with TC <1% (HR, 1.36; 95% CI, 0.79–2.34).
- However, this is not a proper endpoint and was done post-hoc.

Special populations.

- Patients with driver mutations.
- Really controversial area.
- Do this patients benefit from immunotherapy?
- Does prior immunotherapy put patients at risk for pneumonitis if a TKI is subsequently needed?
- Is there any role for using targeted therapy in this setting?
New trials are being done.

- NCT01822496. An NRG trial was designed that used crizotinib and erlotinib before chemoradiation.
- NCT03521154. LAURA study. Osimertinib after chemoradiation.
- Patients with less common drivers. ROS1, BRAF, MET. Data free zone.
Post treatment surveillance.

• No consensus as to what is ideal.
• Could be tailored to what is received as the risk of recurrence.
• Our groups typical schedule is q3 months visit with labs and PE and imaging done q 6 months during the first 2 years.